Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $5.11 in the prior trading day, CureVac N.V (NASDAQ: CVAC) closed at $5.16, up 0.98%. In other words, the price has increased by $0.98 from its previous closing price. On the day, 1.47 million shares were traded. CVAC stock price reached its highest trading level at $5.23 during the session, while it also had its lowest trading level at $5.13.
Ratios:
Our goal is to gain a better understanding of CVAC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.69 and its Current Ratio is at 3.70. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On April 25, 2024, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $12 to $4.
On June 08, 2023, SVB Securities started tracking the stock assigning a Outperform rating and target price of $13.SVB Securities initiated its Outperform rating on June 08, 2023, with a $13 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 07 ’25 when Thaminda Ramanayake bought 6,986 shares for $3.34 per share.
Myriam Mendila bought 17,839 shares of CVAC for $88,019 on Jan 07 ’25. On Jan 07 ’25, another insider, Pierre Kemula, who serves as the affiliate of the company, bought 51,523 shares for $4.93 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVAC now has a Market Capitalization of 1161891328 and an Enterprise Value of 552660224. As of this moment, CureVac’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.22. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.34 while its Price-to-Book (P/B) ratio in mrq is 1.13. Its current Enterprise Value per Revenue stands at 7.812 whereas that against EBITDA is 2.853.
Stock Price History:
The Beta on a monthly basis for CVAC is 1.83, which has changed by 0.6809211 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, CVAC has reached a high of $5.72, while it has fallen to a 52-week low of $2.47. The 50-Day Moving Average of the stock is -3.08%, while the 200-Day Moving Average is calculated to be 12.14%.
Shares Statistics:
The stock has traded on average 823.20K shares per day over the past 3-months and 2591610 shares per day over the last 10 days, according to various share statistics. A total of 225.17M shares are outstanding, with a floating share count of 96.01M. Insiders hold about 57.36% of the company’s shares, while institutions hold 8.92% stake in the company. Shares short for CVAC as of 1763078400 were 959332 with a Short Ratio of 1.17, compared to 1760486400 on 927476. Therefore, it implies a Short% of Shares Outstanding of 959332 and a Short% of Float of 0.8500000000000001.
Earnings Estimates
The market rating of CureVac N.V (CVAC) is currently shaped by the ongoing analysis conducted by 2.0 analysts closely monitoring its performance.
Analysts are recommending an EPS of between -$0.26 and -$0.71 for the fiscal current year, implying an average EPS of -$0.54. EPS for the following year is -$0.5, with 4.0 analysts recommending between -$0.26 and -$0.73.
Revenue Estimates
2 analysts predict $13.35M in revenue for. The current quarter. It ranges from a high estimate of $24.7M to a low estimate of $2M. As of. The current estimate, CureVac N.V’s year-ago sales were $14.5M
A total of 4 analysts have provided revenue estimates for CVAC’s current fiscal year. The highest revenue estimate was $90.85M, while the lowest revenue estimate was $34.14M, resulting in an average revenue estimate of $62.79M. In the same quarter a year ago, actual revenue was $535.2MBased on 5 analysts’ estimates, the company’s revenue will be $88.19M in the next fiscal year. The high estimate is $105.99M and the low estimate is $61.2M.
